BR9907884A - Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen - Google Patents
Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigenInfo
- Publication number
- BR9907884A BR9907884A BR9907884-8A BR9907884A BR9907884A BR 9907884 A BR9907884 A BR 9907884A BR 9907884 A BR9907884 A BR 9907884A BR 9907884 A BR9907884 A BR 9907884A
- Authority
- BR
- Brazil
- Prior art keywords
- generating
- antigen
- response
- immune response
- pneumococcal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO DE VACINA, PROCESSOS PARA GERAR UMA RESPOSTA IMUNE EM UM ANTìGENO PNEUMOCóCICO, PARA AUMENTAR RESPOSTA DE IFN-GAMA EM UMA VACINA PNEUMOCóCICA, E PARA GERAR ANTICORPOS DE FIXAçãO COMPLEMENTAR PARA UMA RESPOSTA PROTETORA A UM PATóGENO, COMPOSIçãO IMUNOGêNICA, E, PROCESSO PARA GERAR UMA RESPOSTA IMUNE EM UM ANTìGENO MENINGOCóCICO". Esta invenção refere-se às composições de vacina compreendendo uma mistrua de antígeno, tal como um antígeno pneumocócico ou meningocócico, e interleucina IL-12, que pode ser adsorvida sobre um mineral em suspensão. O antígeno pneumocócico ou meningocócico pode ser conjugado em uma molécula veículo. Estas composições de vacina modulam a resposta imune protetora ao antígeno."VACCINE COMPOSITION, PROCESSES TO GENERATE AN IMMUNE RESPONSE IN A PNEUMOCOCCY ANTIGEN, TO INCREASE IFN-RANGE RESPONSE IN A PNEUMOCOCCY VACCINE, AND TO GENERATE COMPLEMENTARY FIXING ANTIBODIES, A PROTECTIVE PROTECTION, A PROTECTIVE PROTECTION AND A PROTECTIVE PROTECTIVE PROTECTIVE PROTECTION. GENERATE AN IMMUNE RESPONSE IN A MENINGOCOCCIC ANTIGEN ". This invention relates to vaccine compositions comprising an antigen mix, such as a pneumococcal or meningococcal antigen, and IL-12 interleukin, which can be adsorbed onto a suspended mineral. The pneumococcal or meningococcal antigen can be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7452898P | 1998-02-12 | 1998-02-12 | |
PCT/US1999/002847 WO1999040936A2 (en) | 1998-02-12 | 1999-02-10 | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9907884A true BR9907884A (en) | 2000-10-24 |
Family
ID=22120049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9907884-8A BR9907884A (en) | 1998-02-12 | 1999-02-10 | Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1053015A2 (en) |
JP (3) | JP2002502882A (en) |
KR (1) | KR100585408B1 (en) |
CN (1) | CN1200730C (en) |
AU (1) | AU759391B2 (en) |
BR (1) | BR9907884A (en) |
CA (1) | CA2320223A1 (en) |
IL (2) | IL137809A0 (en) |
WO (1) | WO1999040936A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9907884A (en) * | 1998-02-12 | 2000-10-24 | American Cyanamid Co | Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen |
US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
CZ2002212A3 (en) | 1999-07-22 | 2002-07-17 | The Procter & Gamble Company | Variants of subtilisin protease having amino acid substitutions in defined epitope regions |
CN1373802A (en) | 1999-07-22 | 2002-10-09 | 宝洁公司 | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
MXPA02000842A (en) | 1999-07-22 | 2002-07-30 | Procter & Gamble | Protease conjugates having sterically protected clip sites. |
SI1549338T1 (en) | 2002-10-11 | 2011-04-29 | Novartis Vaccines & Diagnostic | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
EP1961426B1 (en) | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
SI1740217T1 (en) | 2004-04-30 | 2011-10-28 | Novartis Ag | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US8758764B2 (en) | 2005-02-18 | 2014-06-24 | Novartis Vaccines And Diagnostics Srl | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
CN101203529A (en) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN113198012A (en) * | 2005-04-08 | 2021-08-03 | 惠氏有限责任公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2006123164A2 (en) * | 2005-05-19 | 2006-11-23 | The Edward Jenner Institute For Vaccine Research | Lps-binding and bactericidal cytokines and interferons |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
EP2886551A3 (en) | 2008-02-21 | 2015-09-23 | Novartis AG | Meningococcal fhbp polypeptides |
EP3549602A1 (en) | 2009-03-06 | 2019-10-09 | GlaxoSmithKline Biologicals S.A. | Chlamydia antigens |
US8679505B2 (en) | 2009-04-14 | 2014-03-25 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
DK2464658T3 (en) | 2009-07-16 | 2014-12-15 | Novartis Ag | Detoxified escherichia coli immunogens |
NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
US20130022639A1 (en) | 2009-09-30 | 2013-01-24 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
BR112012009014B8 (en) | 2009-09-30 | 2022-10-04 | Novartis Ag | PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
CN102917730A (en) | 2009-10-27 | 2013-02-06 | 诺华有限公司 | Modified meningococcal fHBP polypeptides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP5781542B2 (en) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E. polysaccharide immunogen conjugated to an E. coli carrier protein |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
JP2013529894A (en) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | Method for generating parvovirus B19 virus-like particles |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
EP2655389A2 (en) | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
US9511130B2 (en) | 2011-09-14 | 2016-12-06 | Glaxosmithkline Biologicals Sa | Escherichia coli vaccine combination |
EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
US9694063B2 (en) | 2011-12-08 | 2017-07-04 | Glaxosmithkline Biologicals Sa | Clostridium difficile toxin-based vaccine |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
MX2014010011A (en) | 2012-02-24 | 2014-09-08 | Novartis Ag | Pilus proteins and compositions. |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
WO2013160335A2 (en) | 2012-04-26 | 2013-10-31 | Novartis Ag | Antigens and antigen combinations |
MX2014014067A (en) | 2012-05-22 | 2015-02-04 | Novartis Ag | Meningococcus serogroup x conjugate. |
CN104602702B (en) | 2012-09-18 | 2021-08-27 | 葛兰素史密丝克莱恩生物有限公司 | Outer membrane vesicles |
ES2672996T3 (en) | 2012-10-02 | 2018-06-19 | Glaxosmithkline Biologicals Sa | Non-linear saccharide conjugates |
SG10201702685WA (en) | 2012-10-03 | 2017-04-27 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CA2892688A1 (en) | 2012-11-30 | 2014-06-05 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN114544913B (en) * | 2022-02-23 | 2024-04-09 | 沈阳建筑大学 | Soil investigation encryption sampling distribution optimization method |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
EP0769019A1 (en) * | 1994-07-01 | 1997-04-23 | Rican Limited | Helicobacter pylori antigenic protein preparation and immunoassays |
MX9702396A (en) * | 1994-10-05 | 1997-12-31 | Univ Vanderbilt | Interleukin-12 as an adjuvant for paramyxoviridae vaccines. |
GB9422990D0 (en) * | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Immunogenic compositions |
US5866134A (en) * | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
ES2262181T3 (en) * | 1996-05-31 | 2006-11-16 | National University Of Ireland, Maynooth | IL-12 AS AN ASSISTANT IN THE VACCINE AGAINST THE BORDETELLA PERTUSSIS SPECIES. |
US6438586B1 (en) * | 1996-09-30 | 2002-08-20 | Emc Corporation | File transfer utility which employs an intermediate data storage system |
BR9907884A (en) * | 1998-02-12 | 2000-10-24 | American Cyanamid Co | Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen |
US6303114B1 (en) * | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
-
1999
- 1999-02-10 BR BR9907884-8A patent/BR9907884A/en not_active IP Right Cessation
- 1999-02-10 AU AU25965/99A patent/AU759391B2/en not_active Ceased
- 1999-02-10 JP JP2000531187A patent/JP2002502882A/en active Pending
- 1999-02-10 KR KR1020007008806A patent/KR100585408B1/en not_active IP Right Cessation
- 1999-02-10 WO PCT/US1999/002847 patent/WO1999040936A2/en active IP Right Grant
- 1999-02-10 CN CNB998038792A patent/CN1200730C/en not_active Expired - Fee Related
- 1999-02-10 CA CA002320223A patent/CA2320223A1/en not_active Abandoned
- 1999-02-10 IL IL13780999A patent/IL137809A0/en active IP Right Grant
- 1999-02-10 EP EP99905924A patent/EP1053015A2/en not_active Withdrawn
-
2000
- 2000-08-10 IL IL137809A patent/IL137809A/en not_active IP Right Cessation
-
2009
- 2009-08-24 JP JP2009193167A patent/JP2010006827A/en active Pending
-
2010
- 2010-06-24 JP JP2010144063A patent/JP2010265279A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2010006827A (en) | 2010-01-14 |
EP1053015A2 (en) | 2000-11-22 |
AU2596599A (en) | 1999-08-30 |
CN1292706A (en) | 2001-04-25 |
KR100585408B1 (en) | 2006-06-01 |
IL137809A (en) | 2007-12-03 |
JP2010265279A (en) | 2010-11-25 |
CA2320223A1 (en) | 1999-08-19 |
AU759391B2 (en) | 2003-04-10 |
CN1200730C (en) | 2005-05-11 |
JP2002502882A (en) | 2002-01-29 |
IL137809A0 (en) | 2001-10-31 |
WO1999040936A2 (en) | 1999-08-19 |
KR20010040898A (en) | 2001-05-15 |
WO1999040936A3 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9907884A (en) | Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen | |
PT1187629E (en) | ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE | |
DE60141773D1 (en) | GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS | |
ES2179261T3 (en) | STREPTOCOCCUS EQUI BASED VACCINE. | |
MX9702336A (en) | Vaccine compositions. | |
ZA917356B (en) | Vaccine compositions | |
HUT69938A (en) | Urease-based vaccine against helicobacter infection | |
AU4622693A (en) | Potentiation of immunogenic response | |
DE60045668D1 (en) | Influenza virus vaccine composition | |
BRPI0012196B8 (en) | industrialized article | |
IS4518A (en) | New vaccine formulation | |
BRPI0314373B8 (en) | stable immunogenic product for the induction of antibodies against one or more antigenic proteins in an individual, pharmaceutical, immunogenic and vaccine compositions and process for preparing an immunogenic product | |
BR9907883A (en) | Vaccine composition, process to elicit an immune response to a herpes simplex virus antigen, and immunogenic composition | |
BR0212556A (en) | interleukin-12 as a veterinary vaccine adjuvant | |
EP1017283A4 (en) | Polynucleotide vaccine formulations | |
TW221676B (en) | ||
SE9604322D0 (en) | Bacterial antigens and vaccine compositions II | |
DE60036705D1 (en) | ADJUVANSKOMBINATIONS FOR IMMUNIZATION AND VACCINE | |
BR9905780A (en) | Vaccine leptospira antigens for the prevention of laptospirosis | |
DK1204420T3 (en) | Trehalose-producing prokaryotic cells as vaccines | |
DK0563288T3 (en) | Immunopotentiation of vaccines, in particular pig pleuropneumonia vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 14A E 15A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2255 DE 25/03/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ATE A 21A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |